Protara Therapeutics, Inc. (TARA)
3.90
+0.04
(+1.04%)
USD |
NASDAQ |
Sep 01, 15:49
Protara Therapeutics Cash from Operations (TTM) : -66.13M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -66.13M |
| March 31, 2026 | -63.00M |
| December 31, 2025 | -56.36M |
| September 30, 2025 | -48.72M |
| June 30, 2025 | -44.70M |
| March 31, 2025 | -40.14M |
| December 31, 2024 | -35.81M |
| September 30, 2024 | -35.20M |
| June 30, 2024 | -33.33M |
| March 31, 2024 | -35.05M |
| December 31, 2023 | -37.56M |
| September 30, 2023 | -33.88M |
| June 30, 2023 | -32.67M |
| March 31, 2023 | -28.38M |
| December 31, 2022 | -26.46M |
| September 30, 2022 | -28.34M |
| June 30, 2022 | -29.19M |
| March 31, 2022 | -33.54M |
| December 31, 2021 | -34.50M |
| September 30, 2021 | -34.36M |
| June 30, 2021 | -31.92M |
| March 31, 2021 | -28.18M |
| December 31, 2020 | -23.41M |
| September 30, 2020 | -17.73M |
| Date | Value |
|---|---|
| June 30, 2020 | -15.18M |
| March 31, 2020 | -10.75M |
| December 31, 2019 | -5.011M |
| September 30, 2019 | -8.235M |
| June 30, 2019 | -10.14M |
| March 31, 2019 | -19.18M |
| December 31, 2018 | -23.23M |
| September 30, 2018 | -24.62M |
| June 30, 2018 | -27.43M |
| March 31, 2018 | -20.36M |
| December 31, 2017 | -22.35M |
| September 30, 2017 | -22.23M |
| June 30, 2017 | -22.95M |
| March 31, 2017 | -25.24M |
| December 31, 2016 | -23.69M |
| September 30, 2016 | -23.29M |
| June 30, 2016 | -20.56M |
| March 31, 2016 | -19.59M |
| December 31, 2015 | -17.57M |
| September 30, 2015 | -14.43M |
| June 30, 2015 | -14.23M |
| March 31, 2015 | -12.30M |
| December 31, 2014 | -9.99M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| NovelStem International Corp. | -0.2295M |
| Brainstorm Cell Therapeutics, Inc. | -4.057M |
| Summit Therapeutics, Inc. | -457.02M |
| Kezar Life Sciences, Inc. | -42.03M |
| Clene, Inc. | -15.96M |